Local delivery of cancer-cell glycolytic inhibitors in high-grade glioma

Neuro-Oncology

Volumn 17, Issue 1, 2015, Pages 70-80

  Wicks, Robert T ^a   Azadi, Javad ^a   Mangraviti, Antonella ^a   Zhang, Irma ^a   Hwang, Lee ^a   Joshi, Avadhut ^a   Bow, Hansen ^a   Hutt Cabezas, Marianne ^a   Martin, Kristin L ^a   Rudek, Michelle A ^b   Zhao, Ming ^b   Brem, Henry ^a   Tyler, Betty M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

3 bromopyruvate; Dichloroacetate; Glioma; Glycolytic inhibitor; PCPP:SA

Indexed keywords

3 BROMOPYRUVATE; ANTINEOPLASTIC AGENT; DICHLOROACETIC ACID; LACTIC ACID; POLYMER; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ALKYLATING AGENT; BROMOPYRUVATE; DACARBAZINE; DRUG COMBINATION; PYRUVIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL METABOLISM; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; FEMALE; GLIOMA; GLIOMA CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; LONG TERM CARE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NONHUMAN; RAT; ANALOGS AND DERIVATIVES; ANIMAL; BIODEGRADABLE IMPLANT; BRAIN NEOPLASMS; DRUG ADMINISTRATION ROUTE; DRUG COMBINATION; DRUG EFFECTS; FISCHER 344 RAT; GLIOBLASTOMA; GLYCOLYSIS; KAPLAN MEIER METHOD; METABOLISM; TUMOR CELL LINE;

ABSORBABLE IMPLANTS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DACARBAZINE; DICHLOROACETIC ACID; DRUG ADMINISTRATION ROUTES; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; FEMALE; GLIOBLASTOMA; GLYCOLYSIS; HUMANS; KAPLAN-MEIER ESTIMATE; POLYMERS; PYRUVATES; RATS; RATS, INBRED F344;

EID: 84922572782     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou143     Document Type: Article

References (50)

1. Macmillan Cancer Support. Living after diagnosis-median cancer survival times: An analysis of London School of Hygiene and Tropical Medicine dataset. 2011; http://www.macmillan.org.uk/ Documents/AboutUs/Newsroom/ LivingAfterCancerMedianCancerSurvivalTimes.pdf. Accessed 10 December, 2011.
2. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008; 359(5):492-507.
3. McGirt MJ, Than KD, Weingart JD, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg. 2009;110(3):583-588.
4. Nakashima RA, Paggi MG, Pedersen PL. Contributions of glycolysis and oxidative phosphorylation to adenosine 5-triphosphate production in AS-30D hepatoma cells. Cancer Res. 1984;44(12 Pt 1):5702-5706.
5. Oudard S, Arvelo F, Miccoli L, et al. High glycolysis in gliomas despite low hexokinase transcription and activity correlated to chromosome 10 loss. Br J Cancer. 1996;74(6):839-845.
6. Michelakis ED, Sutendra G, Dromparis P, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med. 2010;2(31):31ra34.
7. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-1033.
8. Kim JW, Dang CV. Multifaceted roles of glycolytic enzymes. Trends Biochem Sci. 2005;30(3):142-150.
9. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer. 2004;4(11):891-899.
10. Shinohara Y, Yamamoto K, Kogure K, et al. Steady state transcript levels of the type II hexokinase and type 1 glucose transporter in human tumor cell lines. Cancer Lett. 1994;82(1):27-32.
11. Wilson JE. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol. 2003; 206:(Pt 12):2049-2057.
12. Wolf A, Agnihotri S, Micallef J, et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med. 2011;208(2):313-326.
13. Ko YH, Pedersen PL, Geschwind JF. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett. 2001;173(1):83-91.
14. Zhang Q, Pan J, North PE, et al. Aerosolized 3-bromopyruvate inhibits lung tumorigenesis without causing liver toxicity. Cancer Prev Res (Phila). 2012;5(5):717-725.
15. Ko YH, Smith BL, Wang Y, et al. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun. 2004;324(1):269-275.
16. El Sayed SM, Abou El-Magd RM, Shishido Y, et al. D-amino acid oxidase gene therapy sensitizes glioma cells to the antiglycolytic effect of 3-bromopyruvate. Cancer Gene Ther. 2012;19(1): 1-18.
17. Lee KH, Park JH, Won R, et al. Inhibition of hexokinase leads to neuroprotection against excitotoxicity in organotypic hippocampal slice culture. J Neurosci Res. 2011;89(1):96-107.
18. Vali M, Vossen JA, Buijs M, et al. Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: a biodistribution and survival study. J Pharmacol Exp Ther. 2008;327(1):32-37.
19. Stacpoole PW. The pharmacology of dichloroacetate. Metabolism. 1989;38(11):1124-1144.
20. Abemayor E, Kovachich GB, Haugaard N. Effects of dichloroacetate on brain pyruvate dehydrogenase. J Neurochem. 1984;42(1):38-42.
21. Bonnet S, Archer SL, Allalunis-Turner J, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 2007;11(1):37-51.
22. Kaufmann P, Engelstad K, Wei Y, et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology. 2006;66(3):324-330.
23. Calcutt NA, Lopez VL, Bautista AD, et al. Peripheral neuropathy in rats exposed to dichloroacetate. J Neuropathol Exp Neurol. 2009; 68(9):985-993.
24. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet. 1995; 345(8956):1008-1012.
25. Sipos EP, Tyler B, Piantadosi S, et al. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemother Pharmacol. 1997;39(5):383-389.
26. Tamargo RJ, Epstein JI, Reinhard CS, et al. Brain biocompatibility of a biodegradable, controlled-release polymer in rats. J Biomed Mater Res. 1989;23(2):253-266.
27. Domb AJ, Amselem S, Shah J, et al. Polyanhydrides-Synthesis and Characterization. Adv Polym Sci. 1993;107:93-141.
28. McMurtry MS, Bonnet S, Wu X, et al. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res. 2004;95(8):830-840.
29. Stacpoole PW, Kerr DS, Barnes C, et al. Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics. 2006;117(5):1519-1531.
30. Brem S, Tyler B, Li K, et al. Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother Pharmacol. 2007;60(5): 643-650.
31. Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clin Pharmacokinet. 2002;41(6):403-419.
32. El Sayed SM, El-Magd RM, Shishido Y, et al. 3-Bromopyruvate antagonizes effects of lactate and pyruvate, synergizes with citrate and exerts novel anti-glioma effects. J Bioenerg Biomembr. 2012;44(1):61-79.
33. Ganapathy-Kanniappan S, Geschwind JF, Kunjithapatham R, et al. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death. Anticancer Res. 2009;29(12):4909-4918.
34. Ahmed NN, Franke TF, Bellacosa A, et al. The proteins encoded by c-akt and v-akt differ in post-translational modification, subcellular localization and oncogenic potential. Oncogene. 1993;8(7):1957-1963.
35. Pastorino JG, Hoek JB, Shulga N. Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res. 2005;65(22):10545-10554.
36. Mathupala SP, Ko YH, Pedersen PL. Hexokinase-2 bound to mitochondria: cancers stygian link to the Warburg Effect and a pivotal target for effective therapy. Semin Cancer Biol. 2009; 19(1):17-24.
37. Shoshan-Barmatz V, Golan M. Mitochondrial VDAC1: function in cell life and death and a target for cancer t herapy. Curr Med Chem. 2012;19(5):714-735.
38. Bhardwaj V, Rizvi N, Lai MB, et al. Glycolytic enzyme inhibitors affect pancreatic cancer survival by modulating its signaling and energetics. Anticancer Res. 2010;30(3):743-749.
39. Xu RH, Pelicano H, Zhou Y, et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 2005;65(2):613-621.
40. Pelicano H, Martin DS, Xu RH, et al. Glycolysis inhibition for anticancer treatment. Oncogene. 2006;25(34):4633-4646.
41. Schaefer NG, Geschwind JF, Engles J, et al. Systemic administration of 3-bromopyruvate in treating disseminated aggressive lymphoma. Transl Res. 2012;159(1):51-57.
42. Katz R, Tai CN, Diener RM, et al. Dichloroacetate, sodium: 3-month oral toxicity studies in rats and dogs. Toxicol Appl Pharmacol. 1981; 57(2):273-287.
43. Tews DS, Nissen A, Kulgen C, et al. Drug resistance-associated factors in primary and secondary glioblastomas and their precursor tumors. J Neurooncol. 2000;50(3):227-237.
44. Liu G, Yuan X, Zeng Z, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer. 2006;5:67.
45. Nakano A, Tsuji D, Miki H, et al. Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells. PLoS One. 2011;6(11):e27222.
46. Le Calve B, Rynkowski M, Le Mercier M, et al. Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression. Neoplasia. 2010;12(9):727-739.
47. Li RY, Chen LC, Zhang HY, et al. MiR-139 inhibits Mcl-1 expression and potentiates TMZ-induced apoptosis in glioma. CNS Neurosci Ther. 2013;19(7):477-483.
48. Liu Z, Zhang YY, Zhang QW, et al. 3-Bromopyruvate induces apoptosis in breast cancer cells by downregulating Mcl-1 through the PI3 K/Akt signaling pathway. Anticancer Drugs. 2014;25(4):447-455.
49. Diehn M, Clarke MF. Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst. 2006; 98(24):1755-1757.
50. Diehn M, Cho RW, Lobo NA, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009;458(7239):780-783.